Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by BearDownAZon Aug 12, 2015 12:47pm
100 Views
Post# 24011246

RE:RE:RE:RE:Scarpa LSD Study

RE:RE:RE:RE:Scarpa LSD StudyThe errors on the slides for the July 31st Scarpa/Hunter Syndrome presentation seem to have been fixed. Either that, or I still don't see the problem. Now it shows the urine GAG levels for normal mice as ~600 ug GAG/mg creatinine and ~1300 ug GAG/mg creatinine for the untreated MPS II disease mice. Very likely both of these groups (normal and "untreated MPS II disease mice) were administered a "vehicle only" or "mock treatement" to mimic the handling and treatment regimes with the exception of the injection not including the enzyme (only whatever buffer or liquid formulation the enzyme is in).

One thing I just picked up on. For the urine GAG slide, they show levels for MPS II disease mice treated with I2S alone, I2S-MTf and I2S-MTfp, but for the liver GAG slide as well as the three brain region slide (corpus callosum, cerebral cortex and thalamus), the group of MPS II disease mice treated with I2S alone (no MTf or MTfp carrier) is not shown. 

I previously wrote that it would have been nice for them to include this additional control group and mistakenly thought that they didn't have this group. However, the fact that they show this group for urine GAG levels leads me to believe they do have this data. Why not show it? Why not highlight how much more effective I2S-MTf and I2S-MTfp are relative to I2S alone in THE BRAIN. Wasn't that the point of the study!

BDAZ
Bullboard Posts